1. Tefferi A, Barbui T. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(9):1465-1487. doi: 10.1002/ajh.27002
2. Harrison CN, Barbui T, Bose P, et al. Polycythaemia vera. Nat Rev Dis Primers. 2025;11(1):26. doi: 10.1038/s41572-025-00608-3
3. Spivak JL. Polycythemia Vera. Curr Treat Options Oncol. 2018;19(2):12. doi: 10.1007/s11864-018-0529-x
4. Kristiansen MH, Kjaer L, Skov V, et al. JAK2V617F mutation is highly prevalent in patients with ischemic stroke. Blood Adv. 2023;7(19):5825-5834. doi: 10.1182/bloodadvances.2023010588
5. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488-2498. doi: 10.1056/NEJMoa1408617
6. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148. doi: 10.1038/nature03546
7. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-1790. doi: 10.1056/NEJMoa051113
8. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005;280(24):22788-22792. doi: 10.1074/jbc.C500138200
9. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356(5):459-468. doi: 10.1056/NEJMoa065202
10. Regimbeau M, Mary R, Hermetet F, Girodon F. Genetic Background of Polycythemia Vera. Genes. 2022;13(4):637. doi: 10.3390/genes13040637
11. Vainchenker W, Constantinescu SN. JAK/STAT signaling in hematological malignancies. Oncogene. 2013;32(21):2601- 2613. doi: 10.1038/onc.2012.347
12. Jamieson CH, Gotlib J, Durocher JA, et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci USA. 2006;103(16):6224-6229. doi: 10.1073/pnas.0601462103
13. Lee TS, Ma WL, Zhang X, Kantarjian H, Albitar M. Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations. Bmc Struct Biol. 2009;9:58. doi: 10.1186/1472-6807-9-58
14. Brooks SA, Luty SB, Lai HY, et al. JAK2V617I results in cytokine hypersensitivity without causing an overt myeloproliferative disorder in a mouse transduction–transplantation model. Exp Hematol. 2016;44(1):24-29. doi: 10.1016/j.exphem.2015.09.006
15. Lee AJ, Kim SG, Nam JY, Yun J, Ryoo HM, Bae SH. Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden. Blood Res. 2021;56(4):259-265. doi: 10.5045/br.2021.2021089
16. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289-2301. doi: 10.1056/NEJMoa0810069
17. Ortmann CA, Kent DG, Nangalia J, et al. Effect of mutation order on myeloproliferative neoplasms. N Engl J Med. 2015;372(7):601-612. doi: 10.1056/NEJMoa1412098
18. Gelsi-Boyer V, Trouplin V, Adelaide J, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol. 2009;145(6):788-800. doi: 10.1111/j.1365-2141.2009.07697.x
19. Stegelmann F, Bullinger L, Schlenk RF, et al. DNMT3A mutations in myeloproliferative neoplasms. Leukemia. 2011;25(7):1217-1219. doi: 10.1038/leu.2011.77
20. Brecqueville M, Cervera N, Gelsi-Boyer V, et al. Rare mutations in DNMT3A in myeloproliferative neoplasms and myelodysplastic syndromes. Blood Cancer J. 2011;1(5):e18. doi: 10.1038/bcj.2011.15
21. Nangalia J, Nice FL, Wedge DC, et al. DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype. Haematologica. 2015;100(11):e438-442. doi: 10.3324/haematol.2015.129510
22. Tefferi A, Guglielmelli P, Lasho TL, et al. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br J Haematol. 2020;189(2):291-302. doi: 10.1111/bjh.16380
23. Tefferi A, Lasho TL, Guglielmelli P, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2016;1(1):21-30. doi: 10.1182/bloodadvances.2016000216
24. Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. New Engl J Med. 2010;362(4):369-370. doi: 10.1056/NEJMc0910063
25. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010;24(6):1128-1138. doi: 10.1038/leu.2010.69
26. Kirschner MM, Schemionek M, Schubert C, et al. Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing. PLoS ONE. 2015;10(4):e0123476. doi: 10.1371/journal.pone.0123476
27. Quintas-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109- 3117. doi: 10.1182/blood-2009-04-214957
28. Fleischman AG. Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm. Mediat Inflamm. 2015;2015:606819. doi: 10.1155/2015/606819
29. Vaidya R, Gangat N, Jimma T, et al. Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis. Am J Hematol. 2012;87(11):1003-1005. doi: 10.1002/ajh.23295
30. Chatain N, Koschmieder S, Jost E. Role of Inflammatory Factors during Disease Pathogenesis and Stem Cell Transplantation in Myeloproliferative Neoplasms. Cancers. 2020;12(8):2250. doi: 10.3390/cancers12082250
31. Rai S, Zhang Y, Grockowiak E, et al. IL-1beta promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells. Blood Adv. 2024;8(5):1234-1249. doi: 10.1182/bloodadvances.2023011338
32. Benabid A, Schneider RK. Inflammation drives pressure on TP53 mutant clones in myeloproliferative neoplasms. Nat Genet. 2023;55(9):1432-1434. doi: 10.1038/s41588-023-01479-8
33. Rahman MF, Yang Y, Le BT, et al. Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm. Nat Commun. 2022;13(1):5347. doi: 10.1038/s41467-022-32928-3
34. Wang Z, Lv Y, Yang E, et al. Metabolic Biomarkers Affecting Cell Proliferation and Prognosis in Polycythemia Vera. Cancers. 2022;14(19):4913. doi: 10.3390/cancers14194913
35. Rao TN, Hansen N, Hilfiker J, et al. JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms. Blood. 2019;134(21):1832-1846. doi: 10.1182/blood.2019000162
36. Zhan H, Ciano K, Dong K, Zucker S. Targeting glutamine metabolism in myeloproliferative neoplasms. Blood Cells Mol Dis. 2015;55(3):241-247. doi: 10.1016/j.bcmd.2015.07.007
37. Flosdorf N, Böhnke J, de Toledo MAS, et al. Proinflammatory phenotype of iPS cell-derived JAK2 V617F megakaryocytes induces fibrosis in 3D in vitro bone marrow niche. Stem Cell Rep. 2024;19(2):224-238. doi: 10.1016/j.stemcr.2023.12.011
38. Schneider RK, Mullally A, Dugourd A, et al. Gli1+ Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target. Cell Stem Cell. 2017;20(6):785-800. doi: 10.1016/j.stem.2017.03.008
39. Wasserman LR, Balcerzak SP, Berk PD, et al. Influence of Therapy on Causes of Death in Polycythemia-Vera. T Assoc Am Physician. 1981;94:30-38.
40. Podoltsev NA, Zhu MX, Zeidan AM, et al. The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera. Blood Adv. 2018;2(20):2681-2690. doi: 10.1182/bloodadvances.2018021436
41. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. New Engl J Med. 2004;350(2):114-124. doi: 10.1056/NEJMoa035572
42. Barbui T, Vannucchi AM, De Stefano V, et al. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. Lancet Haematol. 2021;8(3):E175-E184. doi: 10.1016/S2352-3026(20)30373-2
43. Barbui T, Vannucchi AM, De Stefano V, et al. Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. Nejm Evid. 2023;2(6):EVIDoa2200335. doi: 10.1056/EVIDoa2200335
44. Harrison CN, Nangalia J, Boucher R, et al. Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial. J Clin Oncol. 2023;41(19):3534-3544. doi: 10.1200/Jco.22.01935
45. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera. New Engl J Med. 2015;372(5):426-435. doi: 10.1056/NEJMoa1409002
46. Bellosillo B, Doubek M, Tomuleasa C, et al. JAK2 mutations in polycythemia vera: from molecular origins to inflammatory pathways and clinical implications. Memo- Mag Eur Med Onc. 2025;17(Suppl 4):79-93.doi: 10.1007/s12254-024-01009-0
47. Eaves CJ, Eaves AC. Erythropoietin (Ep) dose-response curves for three classes of erythroid progenitors in normal human marrow and in patients with polycythemia vera. Blood. 1978;52(6):1196-1210.
48. Prchal JF, Axelrad AA. Letter: Bone-marrow responses in polycythemia vera. N Engl J Med. 1974;290(24):1382. doi: 10.1056/nejm197406132902419
49. Lacombe C, Casadevall N, Varet B. Polycythaemia vera: in vitro studies of circulating erythroid progenitors. Br J Haematol. 1980;44(2):189-199. doi: 10.1111/j.1365-2141.1980.tb01201.x
50. Pietra D, Li S, Brisci A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood. 2008;111(3):1686-1689. doi: 10.1182/blood-2007-07-101576
51. Scott LM. The JAK2 exon 12 mutations: A comprehensive review. Am J Hematol. 2011;86(8):668-676. doi: 10.1002/ajh.22063
52. Williams N, Lee J, Moore L, et al. Driver Mutation Acquisition in Utero and Childhood Followed By Lifelong Clonal Evolution Underlie Myeloproliferative Neoplasms. Blood. 2020;136:LAB-1. doi: 10.1182/blood-2020-143813
53. Williams N, Lee J, Mitchell E, et al. Life histories of myeloproliferative neoplasms inferred from phylogenies. Nature. 2022;602(7895):162-168. doi: 10.1038/s41586-021-04312-6
54. Chen D, Weinberg OK. Genomic alterations in blast phase of BCR::ABL1-negative myeloproliferative neoplasms. Int J Lab Hematol. 2023;45(6):839-844. doi: 10.1111/ijlh.14184
55. Hinze A, Rinke J, Crodel CC, et al. Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms. Br J Haematol. 2023;202(2):308-317. doi: 10.1111/bjh.18834
56. Lasho TL, Mudireddy M, Finke CM, et al. Targeted next-generation sequencing in blast phase myeloproliferative neoplasms. Blood Adv. 2018;2(4):370-380. doi: 10.1182/bloodadvances.2018015875
57. Fabre MA, de Almeida JG, Fiorillo E, et al. The longitudinal dynamics and natural history of clonal haematopoiesis. Nature. 2022;606(7913):335-342. doi: 10.1038/s41586-022-04785-z
58. Moliterno AR, Kaizer H, Reeves BN. JAK2V617F allele burden in polycythemia vera: burden of proof. Blood. 2023;141(16):1934-1942. doi: 10.1182/blood.2022017697
59. Sazawal S, Singh K, Chhikara S, Chaubey R, Mahapatra M, Saxena R. Influence of JAK2V617F allele burden on clinical phenotype of polycythemia vera patients: A study from India. South Asian J Cancer. 2019;8(2):127-129. doi: 10.4103/sajc.sajc_161_18
60. Sobieralski P, Wasag B, Leszczynska A, Zuk M, Bieniaszewska M. The molecular profile in patients with polycythemia vera and essential thrombocythemia is dynamic and correlates with disease’s phenotype. Front Oncol. 2023;13:1224590. doi: 10.3389/fonc.2023.1224590
61. Ling VY, Heidel FH, Bywater MJ. Pathogenesis and management of high molecular risk myeloproliferative neoplasms. Haematologica. 2025;110(4):863-876. doi: 10.3324/haematol.2023.283987
62. Ma XY, Zhou ZB, Gu SY, et al. Advances in the Diagnosis and Treatment of Myeloproliferative Neoplasms (MPNs). Cancers. 2025;17(19):3142. doi: 10.3390/cancers17193142
63. Baumeister J, Chatain N, Hubrich A, et al. Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms. Leukemia. 2020;34(4):1062-1074. doi: 10.1038/s41375-019-0629-z
64. Marinaccio C, Suraneni P, Celik H, et al. LKB1/STK11 Is a tumor suppressor in the progression of myeloproliferative neoplasms. Cancer Discov. 2021;11(6):1398-1410. doi: 10.1158/2159-8290.Cd-20-1353
65. Kleppe M, Kwak M, Koppikar P, et al. JAK-STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response. Cancer Discov. 2015;5(3):316-331. doi: 10.1158/2159-8290.Cd-14-0736
66. Funakoshi-Tago M. Analysis of the mechanism of polycythemia vera by studying JAK2 mutant-induced signaling pathway. Yakugaku Zasshi. 2011;131(8):1183- 1187. doi: 10.1248/yakushi.131.1183
67. Meyer T, Ruppert V, Görg C, Neubauer A. Activated STAT1 and STAT5 transcription factors in extramedullary hematopoietic tissue in a polycythemia vera patient carrying the JAK2 V617F mutation. Int J Hematol. 2010;91(1):117- 120. doi: 10.1007/s12185-009-0457-4
68. Röder S, Steimle C, Meinhardt G, Pahl HL. STAT3 is constitutively active in some patients with Polycythemia rubra vera. Exp Hematol. 2001;29(6):694-702. doi: 10.1016/S0301-472x(01)00637-3
69. Shi JH, Yuan BB, Hu WQ, Lodish H. JAK2 V617F stimulates proliferation of erythropoietin-dependent erythroid progenitors and delays their differentiation by activating Stat1 and other nonerythroid signaling pathways. Exp Hematol. 2016;44(11):1044-1058. doi: 10.1016/j.exphem.2016.07.010
70. Dupont S, Massé A, James C, et al. The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood. 2007;110(3):1013- 1021. doi: 10.1182/blood-2006-10-054940
71. Garçon L, Rivat C, James C, et al. Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells. Blood. 2006;108(5):1551-1554. doi: 10.1182/blood-2005-10-009514
72. Guo J, Roberts L, Chen Z, Merta PJ, Glaser KB, Shah OJ. JAK2V617F drives Mcl-1 expression and sensitizes hematologic cell lines to dual inhibition of JAK2 and Bcl-xL. PLoS ONE. 2015;10(3):e0114363. doi: 10.1371/journal.pone.0114363
73. Calabresi L, Balliu M, Bartalucci N. Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells. Methods Cell Biol. 2022;171:81-109. doi: 10.1016/bs.mcb.2022.04.005
74. Stivala S, Codilupi T, Brkic S, et al. Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms. J Clin Investig. 2019;129(4):1596-1611. doi: 10.1172/Jci98785
75. Ugo V, Marzac C, Teyssandier I, et al. Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol. 2004;32(2):179-187. doi: 10.1016/j.exphem.2003.11.003
76. Marty C, Lacout C, Droin N, et al. A role for reactive oxygen species in JAK2V617F myeloproliferative neoplasm progression. Leukemia. 2013;27(11):2187-2195. doi: 10.1038/leu.2013.102
77. Skov V, Thomassen M, Kjaer L, et al. Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms. PLoS ONE. 2022;17(6):e0270669. doi: 10.1371/journal.pone.0270669
78. Rinaldi CR, Rinaldi P, Alagia A, et al. Preferential Nuclear Accumulation of JAK2V617F In CD34+ but Not Granulocytic, Megakaryocytic or Erythroid Cells of Patients with Philadelphia-Negative Myeloproliferative Neoplasia. Blood. 2010;116(26):6023-6026. doi: 10.1182/blood-2010-08-302265
79. Dawson MA, Bannister AJ, Göttgens B, et al. JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin. Nature. 2009;461(7265):819-U879. doi: 10.1038/nature08448
80. He J, Zhang Y. Janus Kinase 2: An Epigenetic ‘Writer’ that Activates Leukemogenic Genes. J Mol Cell Biol. 2010;2(5):231-233. doi: 10.1093/jmcb/mjp054
81. Griffiths DS, Li JA, Dawson MA, et al. LIF-independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease. Nature Cell Biol. 2011;13(1):13-21. doi: 10.1038/ncb2135
82. Dawson MA, Foster SD, Bannister AJ, et al. Three Distinct Patterns of Histone H3Y41 Phosphorylation Mark Active Genes. Cell Rep. 2012;2(3):470-477. doi: 10.1016/j.celrep.2012.08.016
83. Sattler M, Griffin JD. JAK2 Gets Histone H3 Rolling. Cancer Cell. 2009;16(5):365-366. doi: 10.1016/j.ccr.2009.10.009
84. Chen E, Schneider RK, Breyfogle LJ, et al. Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms. Blood. 2015;125(2):327-335. doi: 10.1182/blood-2014-04-567024
85. Abdel-Wahab O, Adli M, LaFave LM, et al. ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2- Mediated Gene Repression. Cancer Cell. 2012;22(2):180-193. doi: 10.1016/j.ccr.2012.06.032
86. Byun JM, Song S, Koh Y, Yoon SS, Kim D. The Temporal Sequence and the Differences in Somatic Mutation Acquisition Determines Clinical Behaviors of JAK2- Positive Myeloproliferative Neoplasms. Anticancer Res. 2019;39(11):6273-6282. doi: 10.21873/anticanres.13837
87. Fisher DAC, Fowles JS, Zhou A, Oh ST. Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms. Front Immunol. 2021;12:683401. doi: 10.3389/fimmu.2021.683401
88. Barosi G, Rosti V, Catarsi P, et al. Reduced CXCR4-expression on CD34-positive blood cells predicts outcomes of persons with primary myelofibrosis. Leukemia. 2021;35(2):468-475. doi: 10.1038/s41375-020-0926-6
89. Burger JA, Spoo A, Dwenger A, Burger M, Behringer D. CXCR4 chemokine receptors (CD184) and α4β1 integrins mediate spontaneous migration of human CD34+ progenitors and acute myeloid leukaemia cells beneath marrow stromal cells (pseudoemperipolesis). Brit J Haematol. 2003;122(4):579-589. doi: 10.1046/j.1365-2141.2003.04466.x
90. Klamer S, Voermans C. The role of novel and known extracellular matrix and adhesion molecules in the homeostatic and regenerative bone marrow microenvironment. Cell Adhes Migr. 2014;8(6):563-577. doi: 10.4161/19336918.2014.968501
91. Cominal JG, Cacemiro MD, Berbel GM, et al. Mesenchymal stromal cells secretory pattern contributes to oncoinflammatory bone marrow microenvironment in polycythemia vera. Hematol Transf Cell. 2026;48(1):106224.doi: 10.1016/j.htct.2025.106224
92. Dirani NA, Soufan F, Jebawi KA, et al. Targeting mitochondrial dysfunction in myeloproliferative neoplasms: current strategies and future directions - a narrative review. Ann Med Surg. 2025;87(11):7386-7395. doi: 10.1097/Ms9.0000000000003984
93. Bose P, Nagler E, Nawaz MS, et al. Results from a US modified Delphi consensus to define disease progression and disease modification in polycythemia Vera. Ann Hematol. 2025;104(10):5063-5075. doi: 10.1007/s00277-025-06641-2
94. Waggoner M. Polycythemia Vera: Thinking Beyond the Hematocrit. J Adv Pract Oncol. 2023;14(5):405-413. doi: 10.6004/jadpro.2023.14.5.5
95. Teng G, Zhou Y, Zhang Y, et al. Thrombosis in patients with post-polycythemia vera myelofibrosis: incidence and risk factors. Thromb Res. 2022;212:38-43. doi: 10.1016/j.thromres.2022.02.006
96. Barbui T, Carobbio A, Thiele J, et al. The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients. Blood Cancer J. 2023;13(1):187. doi: 10.1038/s41408-023-00960-1
97. Rana MS, Iftikhar M, Jadoon Y, et al. The Mutational Landscape in Polycythemia Vera: Phenotype, Genotype, and Prognostic Correlates. Am J Hematol. 2025;100(8):1343- 1353. doi: 10.1002/ajh.27717
98. Soriano G, Heaney M. Polycythemia vera and essential thrombocythemia: new developments in biology with therapeutic implications. Curr Opin Hematol. 2013;20(2):169-175. doi: 10.1097/MOH.0b013e32835d82fe
99. Le Bousse-Kerdiles MC, Martyre MC. Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis. Ann Hematol. 1999;78(10):437-444. doi: 10.1007/s002770050595
100. Méhes G, Tzankov A, Hebeda K, Anagnostopoulos I, Krenács L, Bedekovics J. Platelet-derived growth factor receptor (PDGFR) immunohistochemistry highlights activated bone marrow stroma and is potentially predictive for fibrosis progression in prefibrotic myeloproliferative neoplasia. Histopathology. 2015;67(5):617-624. doi: 10.1111/his.12704
101. Teodorescu P, Pasca S, Jurj A, et al. Transforming growth factor beta-mediated micromechanics modulates disease progression in primary myelofibrosis. J Cell Mol Med. 2020;24(19):11100-11110. doi: 10.1111/jcmm.15526
102. Todor SB, Mihaila RG. Cytokine Landscapes, Immune Dysregulation, and Treatment Perspectives in Philadelphia- Negative Myeloproliferative Neoplasms: A Narrative Review. J Clin Med. 2025;14(17):6328. doi: 10.3390/jcm14176328
103. Colling ME, Tourdot BE, Kanthi Y. Inflammation, Infection and Venous Thromboembolism. Circ Res. 2021;128(12):2017-2036. doi: 10.1161/Circresaha.121.318225
104. Liu Y, Wang YY, Huang G, et al. The role of leukocytes in myeloproliferative neoplasm thromboinflammation. J Leukocyte Biol. 2024;115(6):1020-1028. doi: 10.1093/jleuko/qiae071
105. Hasselbalch HC, Bjorn ME. MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives. Mediat Inflamm. 2015;2015:102476. doi: 10.1155/2015/102476
106. Oyarzún CPM, Heller PG. Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms. Front Immunol. 2019;10:1373. doi: 10.3389/fimmu.2019.01373
107. Drynda A, Surmiak M, Bazan-Socha S, et al. Neutrophils and Platelets as Key Players in the Pathogenesis of ANCA-Associated Vasculitis and Potential Sources of Disease Activity Biomarkers. Diagnostics. 2025;15(15):1905. doi: 10.3390/diagnostics15151905
108. Farina M, Russo D, Hoffman R. The possible role of mutated endothelial cells in myeloproliferative neoplasms. Haematologica. 2021;106(11):2813-2823. doi: 10.3324/haematol.2021.278499
109. Tremblay D, Kosiorek HE, Dueck AC, Hoffman R. Evaluation of Therapeutic Strategies to Reduce the Number of Thrombotic Events in Patients With Polycythemia Vera and Essential Thrombocythemia. Front Oncol. 2021;10:636675. doi: 10.3389/fonc.2020.636675
110. Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874-1881. doi: 10.1038/leu.2013.163
111. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22-33. doi: 10.1056/NEJMoa1208500
112. Gori T. Viscosity, platelet activation, and hematocrit: Progress in understanding their relationship with clinical and subclinical vascular disease. Clin Hemorheol Micro. 2011;49(1-4):37-42. doi: 10.3233/Ch-2011-1455
113. Wolach O, Sellar RS, Martinod K, et al. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci Transl Med. 2018;10(436):eaan8292. doi: 10.1126/scitranslmed.aan8292
114. Massberg S, Grahl L, von Bruehl ML, et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nature Med 2010;16(8):887-U887. doi: 10.1038/nm.2184
115. Papayannopoulos V. Neutrophil extracellular traps in immunity and disease. Nature Rev Immunol. 2018;18(2):134- 147. doi: 10.1038/nri.2017.105
116. Brill A, Fuchs TA, Savchenko AS, et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost. 2012;10(1):136-144. doi: 10.1111/j.1538-7836.2011.04544.x
117. Bar-Natan M, Hoffman R. New insights into the causes of thrombotic events in patients with myeloproliferative neoplasms raise the possibility of novel therapeutic approaches. Haematologica. 2019;104(1):3-6. doi: 10.3324/haematol.2018.205989
118. Cuthbert D, Stein BL. Polycythemia Vera-Associated Complications: Pathogenesis, Clinical Manifestations, And Effects On Outcomes. J Blood Med. 2019;10:359-371. doi: 10.2147/JBM.S189922
119. Lebowa WM, Kuczia P, Lebowa P, Sacha T. Endothelial dysfunction and thrombosis in polycythemia vera. Acta Haematol Pol. 2024;55(6):335-342. doi: 10.5603/ahp.102182
120. Sozer S, Fiel MI, Schiano T, Xu MJ, Mascarenhas J, Hoffman R. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood. 2009;113(21):5246-5249. doi: 10.1182/blood-2008-11-191544
121. Sozer S, Ishii T, Fiel MI, et al. Human CD34+ cells are capable of generating normal and JAK2V617F positive endothelial like cells in vivo. Blood Cells Mol Dis. 2009;43(3):304-312. doi: 10.1016/j.bcmd.2009.08.005
122. Guy A, Gourdou-Latyszenok V, Le Lay N, et al. Vascular endothelial cell expression of JAK2V617F is sufficient to promote a pro-thrombotic state due to increased P-selectin expression. Haematologica. 2019;104(1):70-81. doi: 10.3324/haematol.2018.195321
123. Guadall A, Lesteven E, Letort G, et al. Endothelial Cells Harbouring the JAK2V617F Mutation Display Pro- Adherent and Pro-Thrombotic Features. Thromb Haemost. 2018;118(9):1586-1599. doi: 10.1055/s-0038-1667015
124. Isufi I, Seetharam M, Zhou L, et al. Transforming growth factor-β signaling in normal and malignant Hematopoiesis. J Interf Cytok Res. 2007;27(7):543-552. doi: 10.1089/jir.2007.0009
125. Dong M, Blobe GC. Role of transforming growth factor-beta in hematologic malignancies. Blood. 2006;107(12):4589- 4596. doi: 10.1182/blood-2005-10-4169
126. Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling F. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood. 2002;100(10):3495-3503. doi: 10.1182/blood-2002-04-1133
127. Handa S, Riazat-Kesh YJRA, Butterfield RJ, et al. Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms. Blood. 2024;144:244-244. doi: 10.1182/blood-2024-206688
128. Chen D, Cantu M, Siddon A, Weinberg OK. Mutated Acute Myeloid Leukemia and Blast Phase Myeloproliferative Neoplasm: Distinct Mutation Leads to Poorer Prognosis. Eur J Haematol. 2025;115(1):57-63. doi: 10.1111/ejh.14421
129. Petrides PE. How I Treat Patients with Polycythemia Vera. Leukemia Res. 2014;38:S14-S14. doi: Doi 10.1016/S0145-2126(14)70029-3
130. Tremblay D, Kremyanskaya M, Mascarenhas J, Hoffman R. Diagnosis and Treatment of Polycythemia Vera: A Review. Jama-J Am Med Assoc. 2025;333(2):153-160. doi: 10.1001/jama.2024.20377
131. Verstovsek S, Pemmaraju N, Reaven NL, et al. Real-world treatments and thrombotic events in polycythemia vera patients in the USA. Ann Hematol. 2023;102(3):571-581. doi: 10.1007/s00277-023-05089-6
132. Zwicker JI, Paranagama D, Lessen DS, Colucci PM, Grunwald MR. Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study. Haematologica. 2022;107(5):1106-1110. doi: 10.3324/haematol.2021.279032
133. Petrucci G, Giaretta A, Ranalli P, et al. Platelet thromboxane inhibition by low-dose aspirin in polycythemia vera: Ex vivo and in vivo measurements and in silico simulation. Cts-Clin Transl Sci. 2022;15(12):2958-2970. doi: 10.1111/cts.13415
134. Tremblay D. Cytoreduction for ET and PV: who, what, when, and how ? Hematol-Am Soc Hemat. 2023;(1):660-666. doi: 10.1182/hematology.2023000451
135. Sankar K, Stein BL. Do All Patients With Polycythemia Vera or Essential Thrombocythemia Need Cytoreduction? J Natl Compr Canc Ne. 2018;16(12):1539-1545. doi: 10.6004/jnccn.2018.7073
136. Ferrari A, Carobbio A, Masciulli A, et al. Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis. Haematologica. 2019;104(12):2391-2399. doi: 10.3324/haematol.2019.221234
137. Kiladjian JJ, Klade C, Georgiev P, et al. Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b. Leukemia. 2022;36(5):1408-1411. doi: 10.1038/s41375-022-01528-x
138. Knudsen TA, Hansen DL, Ocias LF, et al. Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial. Blood. 2018;132:885-896. doi: 10.1182/blood-2018-99-111255
139. Brown R, Bennett R, Crean C, et al. The impact of JAK2(V617F) variant allele frequency in MPN patients following PEGylated interferon alpha discontinuation. Br J Haematol. 2025;207(6):2597-2601. doi: 10.1111/bjh.70198
140. Quintás-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera. J Clin Oncol. 2009;27(32):5418-5424. doi: 10.1200/Jco.2009.23.6075
141. Koschmieder S, Schulte C, von der Heyde E, et al. Clinical outcomes of high-risk patients with polycythemia vera after suboptimal response to first-line therapy who switched to ruxolitinib versus nonswitchers: results from the PV-Switch study. Ther Adv Hematol. 2025;16:20406207251342199. doi: 10.1177/20406207251342199
142. Theocharides A, Gisslinger H, De Stefano V, et al. Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study. Eur J Haematol. 2024;112(3):379-391. doi: 10.1111/ejh.14124
143. Mancuso S, Santoro M, Accurso V, et al. Cardiovascular Risk in Polycythemia Vera: Thrombotic Risk and Survival: Can Cytoreductive Therapy Be Useful in Patients with Low-Risk Polycythemia Vera with Cardiovascular Risk Factors? Oncol Res Treat. 2020;43(10):526-529. doi: 10.1159/000509376
144. Benevolo G, Marchetti M, Melchio R, et al. Diagnosis and Management of Cardiovascular Risk in Patients with Polycythemia Vera. Vasc Health Risk Manag. 2023;19:765-778. doi: 10.2147/VHRM.S429995
145. How J, Garcia JS, Mullally A. Biology and therapeutic targeting of molecular mechanisms in MPNs. Blood. 2023;141(16):1922-1933. doi: 10.1182/blood.2022017416
146. Yoon SY, Yoon SS, Yang DH, et al. Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study. Int J Cancer. 2025;157(3):526-533. doi: 10.1002/ijc.35411
147. Illés A, Pinczés LI, Egyed M. A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera. Expert Opin Drug Met. 2021;17(1):3-7. doi: 10.1080/17425255.2021.1839050
148. Suo SS, Fu RF, Qin A, et al. Remarkable Molecular Response in Patients with Polycythemia Vera Treated with Ropeginterferon Alfa-2b. Blood. 2024;144:4563-4563. doi: 10.1182/blood-2024-203148
149. Coltoff A, Mascarenhas J. Fedratinib in 2025 and beyond: indications and future applications. Blood Adv. 2025;9(8):1907-1915. doi: 10.1182/bloodadvances.2024015365
150. Verstovsek S, Courby S, Griesshammer M, et al. A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia. Leuk Res. 2017;60:11-17. doi: 10.1016/j.leukres.2017.05.002
151. Harrison CN, Schaap N, Vannucchi AM, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): A single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol. 2017;4(7):E317-E324. doi: 10.1016/S2352-3026(17)30088-1
152. McClatchy J, Strogantsev R, Wolfe E, et al. Clonal hematopoiesis related TET2 loss-of-function impedes IL1beta-mediated epigenetic reprogramming in hematopoietic stem and progenitor cells. Nat Commun. 2023;14(1):8102. doi: 10.1038/s41467-023-43697-y
153. Wang Y, Zuo X. Cytokines frequently implicated in myeloproliferative neoplasms. Cytokine X. 2019;1(1):100005. doi: 10.1016/j.cytox.2019.100005
154. Baldauf CK, Müller P, Haage TR, et al. Anti-IL-6 cytokine treatment has no impact on elevated hematocrit or splenomegaly in a polycythemia vera mouse model. Blood Adv. 2022;6(2):399-404. doi: 10.1182/bloodadvances.2021004379
155. Shi Z, Liu J, Zhao Y, et al. ASXL1 mutations accelerate bone marrow fibrosis via EGR1-TNFA axis-mediated neoplastic fibrocyte generation in myeloproliferative neoplasms. Haematologica. 2023;108(5):1359-1373. doi: 10.3324/haematol.2021.280320
156. Liu R, Zhang J, Rodrigues Lima F, Zeng J, Nian Q. Targeting neutrophil extracellular traps: A novel strategy in hematologic malignancies. Biomed Pharm. 2024;173:116334. doi: 10.1016/j.biopha.2024.116334
157. Markovic DC, Maslovaric IS, Kovacic M, Petrinovic SV, Ilic VL. Putative Role of Neutrophil Extracellular Trap Formation in Chronic Myeloproliferative Neoplasms. Int J Mol Sci. 2023;24(5):4497. doi: 10.3390/ijms24054497
158. Greenfield G, McMullin MF. Epigenetics in myeloproliferative neoplasms. Front Oncol. 2023;13:1206965. doi: 10.3389/fonc.2023.1206965
159. Kleppe M, Koche R, Zou LH, et al. Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. Cancer Cell. 2018;33(4):785-787. doi: 10.1016/j.ccell.2018.03.024
160. Kapahnke K, Plenge T, Klaus T, et al. The histone-methyltransferase DOT1L cooperates with LSD1 to control cell division in blast-phase MPN. Leukemia. 2025;39(10):2406-2418. doi: 10.1038/s41375-025-02719-y
161. Jutzi JS, Kleppe M, Dias J, et al. LSD1 Inhibition Prolongs Survival in Mouse Models of MPN by Selectively Targeting the Disease Clone. Hemasphere. 2018;2(3):e54. doi: 10.1097/HS9.0000000000000054
162. Aiman W, Ali MA, Basit MA, et al. Efficacy and tolerability of isocitrate dehydrogenase inhibitors in patients with acute myeloid leukemia: A systematic review of clinical trials. Leukemia Res. 2023;129:107077. doi: 10.1016/j.leukres.2023.107077
163. Loscocco GG, Vannucchi AM. Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives. Int J Hematol. 2022;115(5):626-644. doi: 10.1007/s12185-022-03335-7
164. Nasillo V, Riva G, Paolini A, et al. Inflammatory Microenvironment and Specific T Cells in Myeloproliferative Neoplasms: Immunopathogenesis and Novel Immunotherapies. Int J Mol Sci. 2021;22(4):1906. doi: 10.3390/ijms22041906
165. Holmström MO, Hjortso MD, Ahmad SM, et al. The JAK2V617F Mutation Is a Target for Specific T Cells in the JAK2V617F-Positive Myeloproliferative Neoplasms. Leukemia. 2017;31(2):495-498. doi: 10.1038/leu.2016.290
166. Holmström MO, Riley CH, Svane IM, Hasselbalch HC, Andersen MH. The CALR Exon 9 Mutations Are Shared Neoantigens in Patients with CALR Mutant Chronic Myeloproliferative Neoplasms. Leukemia. 2016;30(12):2413-2416. doi: 10.1038/leu.2016.233
167. Holmström MO, Martinenaite E, Ahmad SM, et al. The Calreticulin (CALR) Exon 9 Mutations Are Promising Targets for Cancer Immune Therapy. Leukemia. 2018;32(2):429-437. doi: 10.1038/leu.2017.214
168. Pesini C, Gil-Bellido M, Millan LS, et al. Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms. J Immunother Cancer. 2026;14(1):e012706. doi: 10.1136/jitc-2025-012706
169. Bjørn ME, de Stricker K, Kjær L, Ellemann K, Hasselbalch HC. Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera. Leuk Res Rep. 2014;3(2):73-75. doi: 10.1016/j.lrr.2014.05.003
170. Chen PP, Gao GF, Xu YL, et al. Novel gene signature reveals prognostic model in acute lymphoblastic leukemia. Front Cell Dev Biol. 2022;10:1036312. doi: 10.3389/fcell.2022.1036312
171. Chen P, Cao J, Chen L, et al. Prognostic value of an eighteen-genes panel in acute myeloid leukemia by analyzing TARGET and TCGA databases. Cancer Biomark 2023;36(4):287-298. doi: 10.3233/CBM-220179
172. Thiele J, Kvasnicka HM, Gianelli U, et al. Evolution of WHO diagnostic criteria in “Classical Myeloproliferative Neoplasms” compared with the International Consensus Classification. Blood Cancer J. 2025;15(1):31. doi: 10.1038/s41408-025-01235-7
173. Tefferi A, Strand JJ, Lasho TL, et al. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. Leukemia. 2007;21(9):2074-2075. doi: 10.1038/sj.leu.2404724
174. Lange T, Edelmann A, Siebolts U, et al. JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse. Haematologica. 2013;98(5):722-728. doi: 10.3324/haematol.2012.076901
175. Kubovcakova L, Lundberg P, Grisouard J, et al. Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model. Blood. 2013;121(7):1188-1199. doi: 10.1182/blood-2012-03-415646
176. Chang L, Li WX, Cai H, Li J, Duan MH. Efficacy and safety of pegylated interferon in the treatment of JAK2V617F-positive polycythemia vera with a dose de-escalation strategy: a single-center retrospective study. Front Oncol. 2025;15:1586839. doi: 10.3389/fonc.2025.1586839
177. Zheng TT, Chen PP, Xu YL, et al. Comprehensive analysis of thirteen-gene panel with prognosis value in Multiple Myeloma. Cancer Biomark. 2023;38(4):583-593. doi: 10.3233/Cbm-230115
178. Zhang H, Zhang JX. Comprehensive omics profiling in acute myeloid leukemia: From molecular landscape to clinical translation. Curr Proteom. 2025;22(3). doi: 10.1016/j.curpro.2025.100028
179. Carobbio A, Ferrari A, Masciulli A, Ghirardi A, Barosi G, Barbui T. Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Adv. 2019;3(11):1729-1737. doi: 10.1182/bloodadvances.2019000211
180. De Stefano V, Za T, Rossi E, et al. Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. Am J Hematol. 2010;85(2):97-100. doi: 10.1002/ajh.21593
181. Gangat N, Wolanskyj AP, Schwager SM, Hanson CA, Tefferi A. Leukocytosis at Diagnosis and the Risk of Subsequent Thrombosis in Patients With Low-Risk Essential Thrombocythemia and Polycythemia Vera. Cancer. 2009;115(24):5740-5745. doi: 10.1002/cncr.24664
182. Barbui T, Carobbio A, Finazzi G, et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematol-Hematol J. 2011;96(2):315-318. doi: 10.3324/haematol.2010.031070
183. Kristinsson SY, Landgren O, Samuelsson J, Björkholm M, Goldin LR. Autoimmunity and the risk of myeloproliferative neoplasms. Haematol-Hematol J. 2010;95(7):1216-1220. doi: 10.3324/haematol.2009.020412
184. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis. New Engl J Med. 2010;363(12):1117-1127. doi: 10.1056/NEJMoa1002028
185. Cacemiro MD, Cominal JG, Berzoti-Coelho MG, et al. Differential cytokine network profile in polycythemia vera and secondary polycythemia. Sci Rep-Uk. 2020;10(1):7032. doi: 10.1038/s41598-020-63680-7
186. Jain A, Deo P, Sachdeva MUS, et al. Aberrant expression of cytokines in polycythemia vera correlate with the risk of thrombosis. Blood Cell Mol Dis. 2021;89:102565. doi: 10.1016/j.bcmd.2021.102565
187. Yildirim M, Erdogdu B, Sayin S, et al. Metabolomic Profiling Reveals Distinct Signatures in Primary and Secondary Polycythemia. Metabolites. 2025;15(9):630. doi: 10.3390/metabo15090630
188. La Spina E, Giallongo S, Giallongo C, et al. Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases. Front Oncol. 2023;13:1141610. doi: 10.3389/fonc.2023.1141610
189. Alvarez-Larrán A, Kerguelen A, Hernández-Boluda JC, et al. Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. Brit J Haematol. 2016;172(5):786-793. doi: 10.1111/bjh.13886
190. Greenfield G, McPherson S, Mills K, McMullin MF. The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms. J Transl Med. 2018;16:360. doi: 10.1186/s12967-018-1729-7
191. Guglielmelli P, Mora B, Gesullo F, et al. Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia. Am J Hematol. 2024;99(8):1550-1559. doi: 10.1002/ajh.27400
192. Luque Paz D, Jouanneau-Courville R, Riou J, et al. Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation. Blood Adv. 2020;4(19):4887-4897. doi: 10.1182/bloodadvances.2020002271
193. Braish J, Bose P, Pemmaraju N, et al. Impact of JAK2 allele burden on MF outcome in the era of ruxolitinib. J Clin Oncol. 2024;42(16_suppl):6514-6514. doi: 10.1200/JCO.2024.42.16_suppl.6514
194. Kundranda MN, Tibes R, Mesa RA. Transformation of a Chronic Myeloproliferative Neoplasm to Acute Myelogenous Leukemia: Does Anything Work? Curr Hematol Malig R. 2012;7(1):78-86. doi: 10.1007/s11899-011-0107-9
195. Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013;122(13):2176-2184.doi: 10.1182/blood-2013-03-460154

196. Pasquer H, de Oliveira RD, Vasseur L, et al. Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification. Leukemia. 2024;38(2):326-339. doi: 10.1038/s41375-023-02114-5
197. Barbui T, Ghirardi A, Carobbio A, et al. Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors. Blood Cancer J. 2024;14(1):188. doi: 10.1038/s41408-024-01169-6

198. Padrnos L, Mesa R. Novel agents for the treatment of polycythemia vera: an insight into preclinical research and early phase clinical trials. Expert Opin Inv Drug. 2020;29(8):809-817. doi: 10.1080/13543784.2020.1782886